Compare Vipshop Holdings Ltd - ADR (VIPS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vipshop Holdings Ltd - ADR vs Zimmer Biomet Holdings Inc — how do they compare? Vipshop Holdings Ltd - ADR trades at $12.96 (market cap $6.05B), while Zimmer Biomet Holdings Inc trades at $89.07 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.8× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold Vipshop Holdings Ltd - ADR for 49 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VIPS | ZBH | |
|---|---|---|
Market Cap | $6.05B | $16.95B |
Volume | 3,719,230 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $20.29 | $103.98 |
52-Week Low | $12.09 | $79.58 |
Typical Hold Time | 49 Days | 89 Days |
Enterprise Value | $2.87B | $24.02B |
Dividend Yield | 4.87% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vipshop Holdings (VIPS) trades at $12.98, up 1.61% with mixed technical signals showing neutral overall momentum. The stock trades at attractive valuation multiples including P/E of 4.1x and P/S of 0.4x, supported by strong profitability with 24.4% ROE. Recent earnings showed Q2 2026 miss with $0.12 EPS versus $0.59 expected, reflecting challenging retail conditions as revenue declined to $105.9B in 2025.
The investment case balances deep value metrics against growth headwinds. Analyst consensus targets $16.17 (25% upside) with 54% buy ratings, though recent earnings misses and consumer spending concerns create near-term uncertainty. The company maintains strong cash generation with $9.1B operating cash flow in 2024, supporting shareholder returns.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
